Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma (NCT05296070)
A Phase 2, Open-label, Study Evaluating Safety and Efficacy of the Loncastuximab in Relapsed/Refractory Marginal Zone Lymphoma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- City of Hope National Medical Center — Duarte, California
- University of Miami — Miami, Florida
- Emory University — Atlanta, Georgia
- Vanderbilt University — Nashville, Tennessee
📞 Contact the Study Coordinator
Phone: (305) 243-5247
Email: paa107@miami.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Marginal Zone Lymphoma
- A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma — Duarte, California
- Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma — Milwaukee, Wisconsin
- A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma — Washington D.C., District of Columbia
- Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL) — St Louis, Missouri
- Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) — Miami, Florida
Explore by condition: All Marginal Zone Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.